Literature DB >> 33656628

Endothelial TRPV4 channels prevent tumor growth and metastasis via modulation of tumor angiogenesis and vascular integrity.

Anantha K Kanugula1,2, Ravi K Adapala1, Anurag Jamaiyar1,3, Nina Lenkey1, Brianna D Guarino1, Wolfgang Liedtke4, Liya Yin1,3, Sailaja Paruchuri5, Charles K Thodeti6,7.   

Abstract

Transient receptor potential vanilloid 4 (TRPV4) is a ubiquitously expressed polymodally activated ion channel. TRPV4 has been implicated in tumor progression; however, the cell-specific role of TRPV4 in tumor growth, angiogenesis, and metastasis is unknown. Here, we generated endothelial-specific TRPV4 knockout (TRPV4ECKO) mice by crossing TRPV4lox/lox mice with Tie2-Cre mice. Tumor growth and metastasis were significantly increased in a syngeneic Lewis lung carcinoma tumor model of TRPV4ECKO mice compared to TRPV4lox/lox mice. Multiphoton microscopy, dextran leakage, and immunohistochemical analysis revealed increased tumor angiogenesis and metastasis that were correlated with aberrant leaky vessels (increased width and reduced pericyte and VE-cadherin coverage). Mechanistically, increases in VEGFR2, p-ERK, and MMP-9 expression and DQ gelatinase activity were observed in the TRPV4ECKO mouse tumors. Our results demonstrated that endothelial TRPV4 is a critical modulator of vascular integrity and tumor angiogenesis and that deletion of TRPV4 promotes tumor angiogenesis, growth, and metastasis.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V. part of Springer Nature.

Entities:  

Keywords:  Endothelial cell; Metastasis; Transient receptor potential vanilloid 4; Tumor angiogenesis; Vascular endothelial growth factor receptor 2

Mesh:

Substances:

Year:  2021        PMID: 33656628      PMCID: PMC8295186          DOI: 10.1007/s10456-021-09775-9

Source DB:  PubMed          Journal:  Angiogenesis        ISSN: 0969-6970            Impact factor:   10.658


  30 in total

Review 1.  TRPV4 plays an evolutionary conserved role in the transduction of osmotic and mechanical stimuli in live animals.

Authors:  Wolfgang Liedtke
Journal:  J Physiol       Date:  2005-06-16       Impact factor: 5.182

2.  Mechanosensitive TRPV4 channels stabilize VE-cadherin junctions to regulate tumor vascular integrity and metastasis.

Authors:  Holly C Cappelli; Anantha K Kanugula; Ravi K Adapala; Vibhatsu Amin; Priya Sharma; Priya Midha; Sailaja Paruchuri; Charles K Thodeti
Journal:  Cancer Lett       Date:  2018-10-27       Impact factor: 8.679

3.  TRPV4 channels mediate cardiac fibroblast differentiation by integrating mechanical and soluble signals.

Authors:  Ravi K Adapala; Roslin J Thoppil; Daniel J Luther; Sailaja Paruchuri; J Gary Meszaros; William M Chilian; Charles K Thodeti
Journal:  J Mol Cell Cardiol       Date:  2012-11-08       Impact factor: 5.000

4.  TRPV4-mediated endothelial Ca2+ influx and vasodilation in response to shear stress.

Authors:  Suelhem A Mendoza; Juan Fang; David D Gutterman; David A Wilcox; Aaron H Bubolz; Rongshan Li; Makoto Suzuki; David X Zhang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-12-04       Impact factor: 4.733

5.  TRPV4 channels mediate cyclic strain-induced endothelial cell reorientation through integrin-to-integrin signaling.

Authors:  Charles K Thodeti; Benjamin Matthews; Arvind Ravi; Akiko Mammoto; Kaustabh Ghosh; Abigail L Bracha; Donald E Ingber
Journal:  Circ Res       Date:  2009-04-09       Impact factor: 17.367

6.  Pharmacological inhibition of TRPV4 channel suppresses malignant biological behavior of hepatocellular carcinoma via modulation of ERK signaling pathway.

Authors:  Yu Fang; Guoxing Liu; Chengzhi Xie; Ke Qian; Xiaohua Lei; Qiang Liu; Gao Liu; Zhenyu Cao; Jie Fu; Huihui Du; Sushun Liu; Shengfu Huang; Jixiong Hu; Xundi Xu
Journal:  Biomed Pharmacother       Date:  2018-03-22       Impact factor: 6.529

7.  Activation of mechanosensitive ion channel TRPV4 normalizes tumor vasculature and improves cancer therapy.

Authors:  R K Adapala; R J Thoppil; K Ghosh; H C Cappelli; A C Dudley; S Paruchuri; V Keshamouni; M Klagsbrun; J G Meszaros; W M Chilian; D E Ingber; C K Thodeti
Journal:  Oncogene       Date:  2015-04-13       Impact factor: 9.867

8.  TRPV4 plays a role in breast cancer cell migration via Ca2+-dependent activation of AKT and downregulation of E-cadherin cell cortex protein.

Authors:  W H Lee; L Y Choong; T H Jin; N N Mon; S Chong; C S Liew; T Putti; S Y Lu; C Harteneck; Y P Lim
Journal:  Oncogenesis       Date:  2017-05-22       Impact factor: 7.485

9.  Arterial response to shear stress critically depends on endothelial TRPV4 expression.

Authors:  Veronika Hartmannsgruber; Willm-Thomas Heyken; Michael Kacik; Anuradha Kaistha; Ivica Grgic; Christian Harteneck; Wolfgang Liedtke; Joachim Hoyer; Ralf Köhler
Journal:  PLoS One       Date:  2007-09-05       Impact factor: 3.240

10.  TRPV4 Regulates Breast Cancer Cell Extravasation, Stiffness and Actin Cortex.

Authors:  Wen Hsin Lee; Lee Yee Choong; Naing Naing Mon; SsuYi Lu; Qingsong Lin; Brendan Pang; Benedict Yan; Vedula Sri Ram Krishna; Himanshu Singh; Tuan Zea Tan; Jean Paul Thiery; Chwee Teck Lim; Patrick Boon Ooi Tan; Martin Johansson; Christian Harteneck; Yoon Pin Lim
Journal:  Sci Rep       Date:  2016-06-13       Impact factor: 4.379

View more
  3 in total

Review 1.  TRPV4 Mechanotransduction in Fibrosis.

Authors:  Ravi K Adapala; Venkatesh Katari; Lakshminarayan Reddy Teegala; Sathwika Thodeti; Sailaja Paruchuri; Charles K Thodeti
Journal:  Cells       Date:  2021-11-06       Impact factor: 7.666

2.  Multi-Omics Analysis of the Prognosis and Biological Function for TRPV Channel Family in Clear Cell Renal Cell Carcinoma.

Authors:  Yuxiong Jiang; Dongxu Han; Yifan Zhao; Chen Zhang; Xiujuan Shi; Wenyu Gu
Journal:  Front Immunol       Date:  2022-04-26       Impact factor: 8.786

Review 3.  Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy.

Authors:  Yangfu Jiang; Hongying Zhang; Jiao Wang; Yongliang Liu; Ting Luo; Hui Hua
Journal:  J Hematol Oncol       Date:  2022-03-24       Impact factor: 17.388

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.